Abstract
Treatment options are limited in infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, with carbapenems generally preferred. Disturbingly, however, carbapenem-resistant strains are emerging worldwide. Here we report two clinical isolates, one Escherichia coli and one Klebsiella pneumoniae, each with high-level carbapenem resistance (imipenem minimum inhibitory concentration of 32 microg/mL). They were isolated following imipenem therapy from two hospital patients who had received imipenem therapy in different regions of Turkey. Both isolates produced OXA-48-like carbapenemases, enzymes so far reported only from Turkey. Both isolates also had group 1 CTX-M-type ESBLs and had lost major outer membrane proteins. OXA-48-like carbapenemases appear to be scattered in Turkey and surveillance to determine their prevalence is warranted.
Original language | English |
---|---|
Pages (from-to) | 523-6 |
Number of pages | 4 |
Journal | International Journal of Antimicrobial Agents |
Volume | 31 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2008 |
Keywords
- Anti-Bacterial Agents
- Bacterial Outer Membrane Proteins
- Carbapenems
- DNA, Bacterial
- Drug Resistance, Bacterial
- Escherichia coli
- Escherichia coli Infections
- Female
- Humans
- Klebsiella Infections
- Klebsiella pneumoniae
- Male
- Microbial Sensitivity Tests
- Middle Aged
- Porins
- Reverse Transcriptase Polymerase Chain Reaction
- Transformation, Bacterial
- Turkey
- beta-Lactam Resistance
- beta-Lactamases
- beta-Lactams